0001193125-24-032956.txt : 20240213 0001193125-24-032956.hdr.sgml : 20240213 20240213081531 ACCESSION NUMBER: 0001193125-24-032956 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Benitec Biopharma Inc. CENTRAL INDEX KEY: 0001808898 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39267 FILM NUMBER: 24622681 BUSINESS ADDRESS: STREET 1: 3940 TRUST WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (510) 780-0819 MAIL ADDRESS: STREET 1: 3940 TRUST WAY CITY: HAYWARD STATE: CA ZIP: 94545 8-K 1 d756179d8k.htm 8-K 8-K
false 0001808898 0001808898 2024-02-13 2024-02-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2024

 

 

BENITEC BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39267   84-4620206

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

3940 Trust Way, Hayward, California   94545
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 780-0819

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001   BNTC   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On February 13, 2024, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.

   

Description

99.1    Press Release of Benitec Biopharma Inc. dated February 13, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    BENITEC BIOPHARMA INC.
Date: February 13, 2024     By:  

/s/ Jerel A. Banks

    Name:   Jerel A. Banks
    Title:   Chief Executive Officer
 EX-99.1 2 d756179dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023-

-Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit-

-Second Subject Scheduled to Receive BB-301 in February 2024-

-23 Subjects Enrolled into the Oculopharyngeal Muscular Dystrophy Natural History Study with

Multiple Subjects Eligible for entry into the Phase 1b/2a Clinical Treatment Study in 2024-

HAYWARD, Calif., February 13, 2024 — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its second fiscal quarter ended December 31, 2023. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission.

“In 2023 we formally began the journey towards clinical validation of our Silence and Replace-based approach to the management of genetically defined disorders, and our central goals remain focused on the improvement of the lives of patients suffering from Oculopharyngeal Muscular Dystrophy,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “No dose-limiting toxicities have been observed in the first subject treated with BB-301, and the Data Safety Monitoring Board recommended the continuation of subject enrollment for the Phase 1b/2a Clinical Treatment Study without any modifications to the study. We are grateful to have the opportunity to continue the clinical evaluation of BB-301, and we look forward to reporting interim safety data and efficacy data in mid-2024.”

Operational Updates

The key milestones related to the development of BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related Dysphagia, along with other corporate updates, are outlined below:

BB-301 Clinical Development Program Overview:

 

  •  

The BB-301 Phase 1b/2a clinical development program is currently underway in the United States, and the primary elements of the program are summarized below:

 

  •  

The program comprises approximately 76 weeks of follow-up which we anticipate will consist of:

 

  •  

The OPMD Natural History (NH) Study: 6-month pre-treatment observation periods for the evaluation of baseline disposition and natural history of OPMD-related dysphagia (swallowing impairment) in each study participant.

 

  •  

Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study (NCT06185673). BB-301 will be delivered directly into the pharyngeal constrictor muscles of each study subject.

  •  

Phase 1b/2a Treatment Evaluation: 52-weeks of post-dosing follow-up for conclusive evaluation of the primary and secondary endpoints of the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673), with interim safety and efficacy results expected to be available at the end of each 90-day period following the administration of BB-301.

 

  •  

The OPMD NH Study will characterize the level of dysphagia borne by each OPMD subject at baseline and assess subsequent progression of dysphagia via the use of the following quantitative radiographic measures (i.e., videofluoroscopic swallowing studies or “VFSS”). The VFSS outlined below collectively provide objective assessments of global swallowing function and the function of the pharyngeal constrictor muscles (i.e., the muscles whose functional deterioration drives disease progression in OPMD):

 

  •  

Total Pharyngeal Residue %(C2-4)2

 

  •  

Pharyngeal Area at Maximum Constriction (PhAMPC)

 

  •  

Dynamic Imaging Grade of Swallowing Toxicity Scale (DIGEST)

 

  •  

Vallecular Residue %(C2-4)2, Pyriform Sinus Residue %(C2-4)2, and Other Pharyngeal Residue %(C2-4)2

 

  •  

Normalized Residue Ratio Scale (NRRSv, NRRSp)

 

  •  

Pharyngeal Construction Ratio (PCR)

 

  •  

The OPMD NH Study will also employ clinical measures of global swallowing capacity and oropharyngeal dysphagia, along with two distinct patient-reported outcome instruments targeting the assessment of oropharyngeal dysphagia.

 

  •  

Upon the achievement of 6-months of follow-up in the OPMD NH Study, participants will, potentially, be eligible for enrollment into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673).

 

  •  

BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673):

 

  •  

This first-in-human (FIH) study is evaluating the safety and clinical activity of intramuscular doses of BB-301 administered to subjects with OPMD-related Dysphagia.

 

  •  

The primary endpoint of the FIH Study is safety.

 

  •  

Secondary endpoints are designed to determine the impact of BB-301 on swallowing efficiency, swallowing safety, and pharyngeal constrictor muscle function in subjects diagnosed with OPMD with dysphagia via the use of serial clinical and videofluoroscopic assessments. Critically, each of the clinical and videofluoroscopic assessments employed in the FIH Study will be equivalent to those employed for the OPMD NH Study to facilitate comparative clinical and statistical analyses for each study subject.

  •  

The primary and secondary endpoints will be evaluated during each 90-day period following BB-301 intramuscular injection (Day 1).

 

  •  

The natural history of dysphagia observed for each OPMD NH Study participant, as characterized by the VFSS, clinical assessments of global swallowing capacity, and patient-reported outcome measures conducted during the OPMD NH Study, will serve as the baseline for comparative assessments of safety and efficacy of BB-301 upon rollover from the OPMD NH Study onto the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673).

Corporate Updates:

 

  •  

As of January 2024, 23 subjects have been enrolled into the OPMD NH Study in the United States, and the BB-301 development program is designed to treat 21-to-30 subjects.

 

  •  

In accordance with the Protocol for the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673), a meeting of the Data Safety Monitoring Board (DSMB) was convened in January 2024 following the completion of the 28-day post BB-301 dosing visit. No dose-limiting toxicities were observed in the first subject treated with BB-301, and the DSMB recommended the continuation of subject enrollment for the Phase 1b/2a Clinical Treatment Study without any modifications to the study. Following the DSMB recommendation, a second subject has been scheduled to receive BB-301 in February 2024. The next DSMB meeting is anticipated to occur in June 2024 following the 28-day post BB-301 dosing visit of the third subject in Cohort 1 of the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673).

 

  •  

Interim safety data and efficacy data are expected to become available from the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) in mid-2024.

Financial Highlights

Second Quarter 2024 Financial Results

Total Revenues for the quarter ended December 31, 2023, were $0 compared to $14,000 in licensing revenues collected for the quarter ended December 31, 2022.

Total Expenses for the quarter ended December 31, 2023, were $6.9 million compared to $5.6 million for the quarter ended December 31, 2022. For the quarter ended December 31, 2023, the Company incurred royalties and license fees of $1,000 compared to $0 for the three months ended December 31, 2022. The Company incurred $5.1 million of research and development expenses compared to $3.8 million for the comparable quarter ended December 31, 2022. Research and development expenses relate primarily to ongoing clinical development of BB-301 for the treatment of OPMD. General and administrative expenses were $1.8 million compared to $1.9 million for the quarter ended December 31, 2022.

The loss from operations for the quarter ended December 31, 2023, was $6.9 million compared to a loss of $5.6 million for the quarter ended December 31, 2022. Net loss attributable to shareholders for the quarter ended December 31, 2023, was $6.8 million, or $2.64 per basic and diluted share, compared to a net loss of $5.4 million, or $3.34 per basic and diluted share for the quarter ended December 31, 2022. As of December 31, 2023, the Company had $20.4 million in cash and cash equivalents.

BENITEC BIOPHARMA INC.

Consolidated Balance Sheets

(in thousands, except par value and share amounts)

 

     December 31,
2023		     June 30,
2023		  
     (Unaudited)        

Assets

     

Current assets:

     

Cash and cash equivalents

    $ 20,374     $ 2,477  

Restricted cash

      14       13  

Trade and other receivables

      53       55  

Prepaid and other assets

      355       1,184  
  

 

 

    

 

 

  

Total current assets

      20,796       3,729  

Property and equipment, net

      51       87  

Deposits

      25       25  

Prepaid and other assets

      81       97  

Right-of-use assets

      400       526  
  

 

 

    

 

 

  

Total assets

    $ 21,353     $ 4,464  
  

 

 

    

 

 

  

Liabilities and stockholders’ equity

     

Current liabilities:

     

Trade and other payables

    $ 4,937     $ 3,231  

Accrued employee benefits

      523       472  

Lease liabilities, current portion

      286       275  
  

 

 

    

 

 

  

Total current liabilities

      5,746       3,978  

Lease liabilities, less current portion

      137       284  
  

 

 

    

 

 

  

Total liabilities

      5,883       4,262  
  

 

 

    

 

 

  

Commitments and contingencies (Note 11)

     

Stockholders’ equity:

     

Common stock, $0.0001 par value - 160,000,000 shares authorized; 2,592,434 shares and 1,671,485 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively

      —        —   

Additional paid-in capital

      197,063       168,921  

Accumulated deficit

      (180,641 )      (167,889 ) 

Accumulated other comprehensive loss

      (952 )      (830 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

      15,470       202  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 21,353     $ 4,464  
  

 

 

    

 

 

  

The accompanying notes are an integral part of these consolidated financial statements.

BENITEC BIOPHARMA INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share amounts)

 

     Three Months Ended
December 31,		     Six Months Ended
December 31,		  
     2023     2022     2023     2022  

Revenue:

         

Licensing revenues from customers

    $ —      $ 14     $ —      $ 14  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total revenues

      —        14       —        14  
  

 

 

    

 

 

    

 

 

    

 

 

  

Operating expenses:

         

Royalties and license fees

      1       —        (105 )      —   

Research and development

      5,102       3,761       9,531       6,421  

General and administrative

      1,824       1,863       3,375       3,783  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

      6,927       5,624       12,801       10,204  
  

 

 

    

 

 

    

 

 

    

 

 

  

Loss from operations

      (6,927 )      (5,610 )      (12,801 )      (10,190 ) 

Other income (loss):

         

Foreign currency transaction gain (loss)

      152       161       96       (346 ) 

Interest expense, net

      (6 )      (9 )      (12 )      (18 ) 

Other income (expense), net

      (16 )      50       (34 )      50  

Unrealized loss on investment

      (1 )      (3 )      (1 )      —   
  

 

 

    

 

 

    

 

 

    

 

 

  

Total other income (loss), net

      129       199       49       (314 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    $ (6,798 )    $ (5,411 )    $ (12,752 )    $ (10,504 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Other comprehensive income (loss):

         

Unrealized foreign currency translation gain (loss)

      (172 )      (160 )      (122 )      347  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total other comprehensive income (loss)

      (172 )      (160 )      (122 )      347  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total comprehensive loss

    $ (6,970 )    $ (5,571 )    $ (12,874 )    $ (10,157 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    $ (6,798 )    $ (5,411 )    $ (12,752 )    $ (10,504 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss per share:

         

Basic and diluted

    $ (2.64 )    $ (3.34 )    $ (5.39 )    $ (9.30 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Weighted average number of shares outstanding: basic and diluted

      2,576,347       1,621,280       2,366,706       1,129,926  
  

 

 

    

 

 

    

 

 

    

 

 

  

The accompanying notes are an integral part of these consolidated financial statements.

About BB-301

BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1. The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant expression while providing a functional replacement protein.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Forward Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the initiation and completion of pre-clinical and clinical trials, the timing of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the Company’s ability to satisfy its capital needs through increasing its revenue and obtaining additional financing, given market conditions and other factors, including our capital structure; our ability to continue as a going concern; the length of time over which the Company expects its cash and cash equivalents to be sufficient to execute on its business plan; the impact of the COVID-19 pandemic, the disease caused by the SARS-CoV-2 virus and similar events, which may adversely impact the Company’s business and pre-clinical and clinical trials; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Irina Koffler

LifeSci Advisors

Tel: (917) 734-7387

ikoffler@lifesciadvisors.com

EX-101.SCH 3 bntc-20240213.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 bntc-20240213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 bntc-20240213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 13, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001808898
Document Type 8-K
Document Period End Date Feb. 13, 2024
Entity Registrant Name BENITEC BIOPHARMA INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39267
Entity Tax Identification Number 84-4620206
Entity Address, Address Line One 3940 Trust Way
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code (510)
Local Phone Number 780-0819
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001
Trading Symbol BNTC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bntc-20240213.xsd bntc-20240213_lab.xml bntc-20240213_pre.xml d756179d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d756179d8k.htm": { "nsprefix": "bntc", "nsuri": "http://www.benitecbiopharmainc.com/20240213", "dts": { "schema": { "local": [ "bntc-20240213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "bntc-20240213_lab.xml" ] }, "presentationLink": { "local": [ "bntc-20240213_pre.xml" ] }, "inline": { "local": [ "d756179d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-13_to_2024-02-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d756179d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-13_to_2024-02-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d756179d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.benitecbiopharmainc.com//20240213/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-032956-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-032956-xbrl.zip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d756179d8k_htm.xml IDEA: XBRL DOCUMENT 0001808898 2024-02-13 2024-02-13 false 0001808898 8-K 2024-02-13 BENITEC BIOPHARMA INC. DE 001-39267 84-4620206 3940 Trust Way Hayward CA 94545 (510) 780-0819 false false false false Common Stock, par value $0.0001 BNTC NASDAQ false